Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 25Urinary Bladder Neoplasms 23Ureteral Neoplasms 8Urologic Neoplasms 4Urethral Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Urogenital Neoplasms 2Neoplasm Metastasis 2Muscle Invasive Bladder Urothelial Carcinoma 2Metastatic Urothelial Cancer 2Carcinoma, Renal Cell 2Advanced Bladder Cancer 2Urothelial Cancer 1Urologic Diseases 1Urogenital Diseases 1Urinary Bladder Diseases 1Urachal adenocarcinoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Peripheral Nervous System Diseases 1Penile Squamous Cell Carcinoma (PSCC) 1Penile Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Neoplasms 1Muscle-invasive Bladder Cancer 1Metastatic Urothelial Cancer and Other Malignant Solid Tumors 1Metastatic Castration-resistant Prostate Cancer 1Male Urogenital Diseases 1Female Urogenital Diseases 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 2Biopsy 2pembrolizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1infigratinib 1enfortumab vedotin 1durvalumab 1Vinblastine 1Surgical Procedures, Operative 1Platinum 1Nephroureterectomy 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Doxorubicin 1Disulfides 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Pelvis and Ureter Urothelial Carcinoma × enfortumab vedotin × Genitourinary × Clear all
NCT05775471 2026-02-05

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Recruiting
21 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡